Lactiplantibacillus plantarum CN211 with immunomodulatory and uric acid-lowering functions and its application

Abstract

The present invention provides a Lactiplantibacillus plantarum CN211 with immunomodulatory and uric acid-lowering functions and its applications. The Lactiplantibacillus plantarum is Lactiplantibacillus plantarum CN211, which is preserved in the China Center for Type Culture Collection. The preservation date is April 7, 2024, and the preservation number is CCTCC NO: M 2024642. Experimental results show that the Lactiplantibacillus plantarum CN211 has excellent acid and bile salt tolerance and is safe for humans; it has outstanding antibacterial effects and can effectively inhibit Streptococcus anginosus, Vibrio parahaemolyticus, and / or Helicobacter pylori; it can effectively reduce uric acid and relieve symptoms of hyperuricemia; it has a protective effect on kidney injury and can significantly improve the antioxidant capacity of the liver; especially when used in combination with Bifidobacterium longum subsp. longum CN973, the two have a synergistic effect, and the regulation of immune function and the improvement of liver antioxidant capacity are significantly better.

Description

Technical Field

[0001] The present invention belongs to the technical field of Lactiplantibacillus plantarum, and particularly relates to a Lactiplantibacillus plantarum CN211 with immunomodulatory and uric acid-lowering functions and its application. Background Art

[0002] The body's immunity refers to the overall activity of the human immune system, which plays an important role in protecting the human body from external pathogens, preventing the occurrence of diseases, and maintaining a healthy state. The functional characteristics of the body's immunity mainly include: 1. Identifying and defending against pathogens: By producing antibodies, cytokines, and other immune molecules, it can identify and attack invading pathogens, including bacteria, viruses, fungi, and parasites, etc. 2. Repairing damaged tissues: The immune system can identify and repair damaged tissues and cells to help the body recover health. This is usually achieved by generating stem cells, regulating apoptosis, and promoting tissue regeneration, etc. 3. Regulating autoimmunity: The immune system also needs to maintain tolerance to its own tissues while identifying and attacking foreign pathogens to avoid the occurrence of autoimmune diseases. Factors such as nutrition, genetics, environment, mood, lifestyle, and age all affect the body's immunity. Low body immunity will be unable to effectively resist infections and diseases, leading to the occurrence of many diseases.

[0003] Hyperuricemia is a metabolic disease caused by purine metabolism disorders, resulting in the concentration of uric acid in the blood exceeding the normal range. Currently, a blood uric acid concentration exceeding 420 μmol / L (7 mg / dl) is defined as hyperuricemia. The main clinical symptom of hyperuricemia is an increase in blood uric acid. When the condition develops into gout, clinical manifestations such as acute arthritis and tophi may occur. The accompanying symptoms are mostly obesity, type 2 diabetes, dyslipidemia, hypertension, and arteriosclerosis, etc. Asymptomatic hyperuricemia is generally detected during physical examinations, and patients only have an increase in blood uric acid without other symptoms. Therefore, hyperuricemia is extremely harmful to the human body. The gut microbiota is related to various diseases and also plays an important role in the metabolism of purines and uric acid. Gout patients have different gut microbiome patterns, which are characterized by a significant reduction in bacteria expressing uricase genes. In addition, changes in the gut microbiota can affect the expression of UA transporters (such as ABCG2 and GLUT9) in the gut and the systemic inflammatory response. Therefore, it is worthy of further research to achieve the purpose of intervening in hyperuricemia by regulating the gut microbiota. Summary of the Invention

[0004] Object of the Invention: Aiming at the problems existing in the prior art, the present invention provides a Lactiplantibacillus plantarum CN211 with immunomodulatory and uric acid-lowering functions and its application.

[0005] Technical Solution: To achieve the above object of the invention, the present invention adopts the following technical solutions:

[0006] In a first aspect, the present invention provides a Lactiplantibacillus plantarum with immunomodulatory and uric acid-lowering functions, which is Lactiplantibacillus plantarum CN211, deposited in the China Center for Type Culture Collection on April 7, 2024, with the deposit number CCTCC NO: M 2024642.

[0007] In a second aspect, the present invention provides a composition comprising the above-mentioned Lactiplantibacillus plantarum CN211.

[0008] In a third aspect, the present invention provides the use of the above-mentioned Lactiplantibacillus plantarum CN211 and the above composition in the preparation of immunomodulatory products.

[0009] In a fourth aspect, the present invention provides the use of the above-mentioned Lactiplantibacillus plantarum CN211 and the above composition in the preparation of uric acid-lowering products; preferably, the use is in the preparation of products for alleviating the symptoms of hyperuricemia.

[0010] In a fifth aspect, the present invention provides the use of the above-mentioned Lactiplantibacillus plantarum CN211 and the above composition in the preparation of products for protecting against kidney injury.

[0011] In a sixth aspect, the present invention provides the use of the above-mentioned Lactiplantibacillus plantarum CN211 and the above composition in the preparation of products for enhancing the antioxidant capacity of the liver.

[0012] In a seventh aspect, the present invention provides the use of the above-mentioned Lactiplantibacillus plantarum CN211 and the above composition in the preparation of bacteriostatic agents; preferably, the bacteriostatic agent can inhibit Streptococcus anginosus, Vibrio parahaemolyticus, and / or Helicobacter pylori.

[0013] In an eighth aspect, the present invention provides a composition comprising the above-mentioned Lactiplantibacillus plantarum CN211 and Bifidobacterium longum subsp. longum CN973, and the Bifidobacterium longum subsp. longum CN973

[0014] (Bifidobacterium longum subsp. longum CN973) was deposited in the China Center for Type Culture Collection on May 28, 2024, with the deposit number CCTCC NO: M 20241083.

[0015] In a ninth aspect, the present invention provides the use of the composition comprising Lactiplantibacillus plantarum CN211 and Bifidobacterium longum subsp. longum CN973 in the preparation of immunomodulatory products.

[0016] Tenth aspect, the present invention provides the application of the composition comprising Lactiplantibacillus plantarum CN211 and Bifidobacterium longum subsp. longum CN973 in the preparation of a product for improving the antioxidant capacity of the liver.

[0017] The products in the present invention include foods, bacteriostatic agents, drugs, etc.

[0018] Beneficial effects: Compared with the prior art, the present invention provides a novel Lactiplantibacillus plantarum CN211, which has immunomodulatory and uric acid-lowering functions. Experimental results show that this Lactiplantibacillus plantarum CN211 has excellent acid and bile salt tolerance and is safe for humans; it has prominent bacteriostatic effects and can effectively inhibit Streptococcus anginosus, Vibrio parahaemolyticus, and / or Helicobacter pylori; it can effectively reduce uric acid and relieve the symptoms of hyperuricemia; it has a protective effect on kidney injury, and can significantly improve the antioxidant capacity of the liver; especially when combined with Bifidobacterium longum subsp. longum CN973, the two have a synergistic effect, and the regulation of immune function and the improvement of the antioxidant capacity of the liver are significantly better. Description of the Drawings

[0019] Figure 1 Gram staining of Lactiplantibacillus plantarum CN211.

[0020] Figure 2 Phylogenetic tree of Lactiplantibacillus plantarum CN211.

[0021] Figure 3 Comparison of body weights and serum uric acid (SUA) concentrations of mice in each group.

[0022] Figure 4 Comparison of blood urea nitrogen (BUN) and serum creatinine (CRE) concentrations of mice in each group.

[0023] Figure 5 Comparison of serum xanthine oxidase (XOD) and adenosine deaminase (ADA) activities of mice in each group.

[0024] Figure 6 Statistical result chart of serum immunoglobulin IgG content of mice in each group.

[0025] Figure 7 Statistical result chart of serum immunoglobulin IgA content of mice in each group.

[0026] Figure 8 Statistical result chart of the total antioxidant capacity of the livers of mice in each group.

[0027] Figure 9 Statistical result chart of the glutathione peroxidase content of the livers of mice in each group.

[0028] Figure 10 Statistical result chart of the superoxide dismutase content of the livers of mice in each group. Detailed implementation mode

[0029] The technical solution of the present invention will be further described in detail below in conjunction with the accompanying drawings and embodiments.

[0030] Example 1 Screening of uric acid-decomposable strains

[0031] Prepare a strain screening medium capable of decomposing uric acid. Taking the MRS medium as a reference, remove the glucose in the MRS medium and replace it with uric acid as the carbon source. The component ratio of the screening medium MRS-C is: peptone 10.0 g / L, beef extract powder 5.0 g / L, yeast extract powder 4.0 g / L, uric acid 10 g / L, dipotassium hydrogen phosphate 2.0 g / L, trisodium citrate 2.0 g / L, sodium acetate 5.0 g / L, magnesium sulfate 0.2 g / L, manganese sulfate 0.05 g / L, Tween 80 1.0 g / L. 15.0 g / L of agar is additionally added to the agar solid medium. Spread and culture the collected natural fermented dairy product samples on the MRS-C agar medium for 48 h. The same sample is spread in parallel 2 times and cultured in an anaerobic environment and a 5% oxygen environment respectively, and the culture temperature is 35-37 °C. Select single colony strains and place them in 15 ml of MRS liquid medium. Place the selected single colonies in a shaker at 35-37 °C and culture for 8-10 h to obtain the fermentation broth. By detecting the OD of the fermentation broth 600 and observing the bacterial count in the fermentation broth by microscope comparison, discard the samples with poor liquid fermentation effect or no obvious bacterial body amplification, take 0.5 ml of the remaining fermentation broth for standby of bacterial species sequencing identification, take 2 ml and add 2 ml of pre-cooled 30%-40% glycerol solution, and freeze it at -80 °C for standby preservation of alternative bacterial species. A total of 65 single-strain culture solutions are obtained, numbered successively as CN201-CN265.

[0032] Example 2 Screening of acid- and bile salt-tolerant strains

[0033] Culture and activate the 65 strains screened in Example 1 in the MRS medium for 2 generations, and then adjust the bacterial liquid concentration to 1.0×10 8 CFU / mL. Take 1 mL of the bacterial suspension, centrifuge it to collect the bacterial cells, and inoculate them into 1 mL of artificial gastric juice and artificial bile salt solution respectively, and mix well and digest at 37 °C. The artificial gastric juice is PBS solution added with 0.3% pepsin, adjusted to pH 2.5 with 1 mol / L HCl, then fully dissolved and filtered through a 0.22 μm microporous filter membrane for sterilization and standby. The artificial bile salt is 0.5% normal saline added with 0.1% trypsin and 0.3% bovine bile powder, adjusted to pH 8.0, then fully dissolved and filtered through a 0.22 μm microporous filter membrane for sterilization and standby. At the same time, detect the viable bacteria count of the digestive juices at 0 h and 3 h respectively, calculate the survival rate, and remove the strains with weak gastrointestinal tolerance. The evaluation results of the strains with strong gastrointestinal tolerance are shown in Table 1.

[0034] Table 1 Gastrointestinal tolerance survival rates of each strain

[0035] Strain Artificial gastric juice (pH = 2.5) Artificial bile (pH = 8.0) CN206 73.64±3.26 88.14±2.94 CN211 92.37±2.52 97.58±1.46 CN235 72.19±2.04 93.40±2.52 CN238 82.86±2.89 84.85±1.86 CN247 93.24±4.32 62.92±4.33

[0036] Preservation, identification, and deposit of the strain in Example 3

[0037] Combined with the evaluation results during the screening of strains in Examples 1-2, the CN211 strain, which has both uric acid-decomposing ability and high gastrointestinal tolerance, was preserved as the target strain. The result of Gram staining was Gram-positive, as Figure 1 shown. And 16S rRNA molecular biology identification was carried out. Using the published 16S universal primers (primer sequences are: 8F: 5’-AGAGTTTGATCCTGGCTC A-3’; 1510R: 5’-GGTTACCTTGTTACGACTT-3’), the 16S rDNA gene sequence of strain BX8 was amplified and sequenced. The PCR amplification product was sent to Shanghai Sangon Biotech Co., Ltd. for sequencing and identification. The nucleotide sequence of the 16S rDNA of strain CN211 is Sequence 1 in the sequence listing; after 16S rDNA gene alignment, the similarity rate with Lactiplantibacillus plantarum in Genebank reached 99%; combined with microbial system identification, strain CN211 was determined to be a Lactiplantibacillus plantarum, named Lactiplantibacillus plantarum CN211, its 16S rDNA is as shown in SEQ ID NO.1, Gram staining is as Figure 1 shown, and the phylogenetic tree is as Figure 2 shown.

[0038] The biologically identified Lactiplantibacillus plantarum CN211 was deposited. This strain was deposited at the China Center for Type Culture Collection (abbreviation: CCTCC) on April 7, 2024, with the deposit number CCTCC NO: M 2024642, and the deposit address is Wuhan University, Wuhan City, Hubei Province, People's Republic of China.

[0039] Example 4 Intestinal mucosa adhesion experiment

[0040] Lactobacillus plantarum CN211, Lactobacillus plantarum 229v, and Lactobacillus plantarum LP-115 were selected for the intestinal mucosa adhesion experiment. After each strain was cultured at 37°C for 3 h, scanning electron microscopy analysis showed that all strains had the phenomenon of adhering to the intestinal mucosa. The adhesion rate of Lactobacillus plantarum CN211 to the intestinal mucosa was about 87%, which was significantly better than the other two strains, 229v and LP-115. The adhesion rates of each strain to the intestinal mucosa are shown in Table 2.

[0041] Table 2 Adhesion rate of Lactobacillus plantarum CN211 to the intestinal mucosa

[0042] CN211 229v LP-115 Adhesion rate (%) 86.95±4.42 63.24±3.52 72.49±5.23

[0043] Example 5 Antibacterial ability test of Lactobacillus plantarum NKK20 against Enterobacter cloacae

[0044] Lactobacillus plantarum 229v was selected as the control test strain for Lactobacillus plantarum CN211. They were respectively inoculated in 50 ml of MRS liquid medium and cultured at 37°C for 16 h. Then the fermentation broth was centrifuged at 10,000 r / min for 10 min, and the supernatant and bacterial cells were collected separately. The bacterial cells were washed twice with 0.9% sterile saline and then prepared into a bacterial suspension with an OD 600 of 0.5 - 0.8 and stored at 4°C for later use.

[0045] Streptococcus anginosus ATCC 9895, Vibrio parahaemolyticus ATCC17802, and Helicobacter pylori SS1 were selected as the test strains for the in vitro antibacterial experiment. The antibacterial circle test was carried out on the fermentation supernatant and bacterial suspension of each strain by the agar punching method. The MRS culture medium was adjusted with lactic acid to have the same pH value as the supernatant as the blank control, and a 0.05 mg / mL erythromycin solution was used as the positive control for inhibiting Streptococcus anginosus ATCC 9895, Vibrio parahaemolyticus ATCC17802, and Helicobacter pylori SS1. The antibacterial results of each strain are shown in Table 3.

[0046] Compared with the positive control group and the blank control group, the bacterial suspension and supernatant of Lactobacillus plantarum CN211 had significant antibacterial properties against Streptococcus anginosus, Vibrio parahaemolyticus, and Helicobacter pylori. Moreover, the antibacterial ability of the bacterial suspension of Lactobacillus plantarum CN211 against the three pathogenic bacteria was significantly better than that of Lactobacillus plantarum 229v. It can be seen that the fermentation metabolites of Lactobacillus plantarum CN211 contain antibacterial components, and the bacterial cells can still inhibit pathogenic bacteria, which can be used in the intervention preparation for inhibiting pathogenic bacteria and regulating the flora.

[0047] Table 3 Evaluation of the antibacterial effect of fermented Lactobacillus mucosae UN-P

[0048]

[0049] Note: a is significant compared to the blank control, and b is significant compared to 229v

[0050] Example 6 Hemolysis test of Lactiplantibacillus plantarum CN211

[0051] Inoculate the preserved Lactiplantibacillus plantarum CN211 into 5 mL of MRS at an inoculation amount of 2%. Use Enterococcus faecalis (β-hemolytic, CICC 23658, purchased from China Center for Industrial Culture Collection) as the positive control and the blank medium as the negative control. All strains were anaerobically cultured in MRS medium at 37 °C for 12 h to obtain activated strains. Take 2.5 μL of each activated strain and inoculate it onto Columbia blood agar plates (Shanghai KemaJia Microbial Technology Co., Ltd.), with 3 parallels set in each group. Observe after anaerobic culture at 37 °C for 48 h. A clear and completely transparent hemolysis ring formed around the colonies of the positive control strain, which is β-hemolysis; the medium around the colonies of Lactiplantibacillus plantarum CN211 did not change, which is γ-hemolysis, that is, non-hemolysis. Therefore, there is no hemolysis risk for human administration.

[0052] Example 7 Antibiotic susceptibility test of Lactiplantibacillus plantarum CN211

[0053] According to the requirements of the antibiotic susceptibility test in the "General Chapter of Microecological Live Bacterial Preparations" in the third part of the "Chinese Pharmacopoeia" (2020 edition), use MRS medium and adopt the agar diffusion disc method to determine the antibiotic susceptibility of the strain, and judge the antibiotic susceptibility level of the strain according to the size of the inhibition zone.

[0054] The results showed that Lactiplantibacillus plantarum CN211 was sensitive to 6 antibiotics, namely penicillin, imipenem, erythromycin, tetracycline, levofloxacin, and ampicillin, and was intermediate to 3 antibiotics, namely vancomycin, ceftriaxone, and clindamycin.

[0055] Example 8 Intervention effect of Lactiplantibacillus plantarum CN211 on hyperuricemia

[0056] Select 24 male Kunming mice (6 weeks old, 25 ± 2 g), and randomly divide the mice into 3 groups (n = 8 mice / group): negative control group (NC), hyperuricemia group (HUA), and CN211 treatment group (CN211). The HUA group and the CN211 group were modeled for hyperuricemia. The modeling method was to suspend potassium oxonate and adenine in a 0.5% sodium carboxymethylcellulose solution, and give 0.3 ml of potassium oxonate (250 mg / kg) and adenine (75 mg / kg) solution by gavage every day for 14 days. The mice in the NC group were given an equal volume of 0.5% sodium carboxymethylcellulose solution for 14 days. The mice in the CN211 group were given 0.3 ml of PBS bacterial solution (containing Lactiplantibacillus plantarum 1.0×10 9(CFU). Mice in the NC group and the HUA group were given an equal volume of sterile PBS. After 14 consecutive days of intervention, the mice were sacrificed, weighed, and blood was collected from the ophthalmic vein to detect the serum uric acid (SUA) concentration. The results are as Figure 3 shown.

[0057] Body weight is a macroscopic indicator of the overall health status of mice. Compared with the mice in the NC group, the body weight of the mice in the HUA group was significantly reduced, indicating a poorer health status. The intervention treatment of CN211 alleviated the weight loss observed in HUA mice, indicating the beneficial effect of Lactiplantibacillus plantarum CN211 on the overall health status of mice. Similarly, compared with the mice in the NC group, the serum uric acid (SUA) concentration of the mice in the HUA group was significantly increased, indicating the success of the HUA mouse model. At the same time, oral administration of Lactiplantibacillus plantarum CN211 significantly reduced the serum uric acid (SUA) level, thus confirming that Lactiplantibacillus plantarum CN211 can reduce serum uric acid (SUA).

[0058] Example 9 Protective effect of Lactiplantibacillus plantarum CN211 on kidney injury caused by HUA

[0059] Blood urea nitrogen (BUN) and serum creatinine (CRE) are important indicators of kidney injury. The serum of each group of mice collected in Example 8 was detected for the concentrations of blood urea nitrogen (BUN) and serum creatinine (CRE). The results are as Figure 4 shown. The results showed that compared with the NC mice, the levels of blood urea nitrogen (BUN) and serum creatinine (CRE) in the HUA group were significantly increased. Oral administration of Lactiplantibacillus plantarum CN211 effectively reversed the increase in the levels of blood urea nitrogen (BUN) and serum creatinine (CRE) caused by HUA, indicating that Lactiplantibacillus plantarum CN211 has a protective effect on kidney injury.

[0060] Example 10 Alleviating effect of Lactiplantibacillus plantarum CN211 on hyperuricemia

[0061] Since uric acid (UA) is mainly synthesized in the liver, xanthine oxidase (XOD) and adenosine deaminase (ADA) in the liver are two essential enzymes for synthesizing uric acid. The activities of xanthine oxidase (XOD) and adenosine deaminase (ADA) in the serum of each group of mice collected in Example 8 were detected. The results are as Figure 5 shown. Compared with the control group (NC) mice, the activities of xanthine oxidase (XOD) and adenosine deaminase (ADA) in the hyperuricemia (HUA) mice were significantly increased, while the intervention of CN211 inhibited the activities of xanthine oxidase (XOD) and adenosine deaminase (ADA). That is, it indicates that oral administration of Lactiplantibacillus plantarum CN211 can effectively reduce the serum uric acid (SUA) level and alleviate the symptoms of hyperuricemia (HUA).

[0062] Example 11 Immunomodulatory effect of Lactiplantibacillus plantarum CN211

[0063] Forty-eight healthy female Kunming mice were selected and randomly divided into 6 groups of equal size after 2 weeks of adaptive feeding. One group was used as the blank control group, and the remaining 5 groups were orally gavaged with cyclophosphamide at a dose of 100 mg / kg for 3 consecutive days to establish an animal model of immunosuppressed mice. Then, the mice in each group were intervened according to the experimental method shown in Table 8, with the corresponding bacterial solution concentration being 1.0×10 9 CFU / day / mouse for 1 week. The mice were sacrificed and samples were collected. After blood was taken from the orbital cavity of the mice and left to stand at room temperature for 2 h, the samples were centrifuged at 2000×g for 10 min, and the supernatant was used for enzyme-linked immunosorbent assay (ELISA) and biochemical analysis. The results are as shown in Figure 6 and Figure 7 . Compared with the control groups BL1 and BL2, after intervention with each probiotic group, the levels of serum immunoglobulin IgG and serum immunoglobulin IgA in the mice were increased to varying degrees, and the effect of the TE3 group was better than that of other single-strain interventions or combined interventions. That is, the combination of Lactiplantibacillus plantarum CN211 and Bifidobacterium longum subsp. longum CN973 can more significantly increase the expression level of immunoglobulins in the serum and improve the body's immunity.

[0064] Table 4 Experimental groups and intervention methods

[0065]

[0066] Example 12 Analysis of liver antioxidant capacity

[0067] Based on the experimental mouse intervention protocol in Example 11, the liver organs of the mice were removed, rinsed with nuclease-free water, and 10% (w / v) homogenates of the liver were prepared by adding sterile 0.9% saline solution. The liver antioxidant indexes of total antioxidant capacity (T-AOC), glutathione peroxidase (GSH-PX), and superoxide dismutase (SOD) were detected. The results are respectively as shown in Figure 8 and Figure 9 and Figure 10 . It can be seen from the figure that compared with the control group, after intervention with each probiotic group, the total antioxidant capacity, glutathione peroxidase, and superoxide dismutase contents of the mice were increased to varying degrees, and the effect of the group of Bifidobacterium longum subsp. longum CN973 combined with Lactiplantibacillus plantarum CN211 was better than that of other single strains or combinations. It shows that Bifidobacterium longum subsp. longum CN973 combined with Lactiplantibacillus plantarum CN211 involved in the present invention can significantly improve the liver antioxidant capacity.

[0068] The embodiments of the present invention have been described in detail in connection with specific embodiments. However, the present invention is not limited to the above embodiments, and various changes can be made without departing from the spirit of the present invention within the scope of knowledge possessed by those of ordinary skill in the art.

Claims

1. A Lactiplantibacillus plantarum with the functions of enhancing the body's immunity and reducing uric acid, characterized in that, The Lactiplantibacillus plantarum is Lactiplantibacillus plantarum CN211, which is deposited in the China Center for Type Culture Collection. The deposition date is April 7, 2024, and the deposition number is CCTCC NO: M 2024642.

2. A composition, characterized in that, The composition contains the Lactiplantibacillus plantarum CN211 described in claim 1.

3. Use of the Lactiplantibacillus plantarum CN211 described in claim 1 and the composition described in claim 2 in the preparation of a product for enhancing body immunity.

4. Use of the Lactiplantibacillus plantarum CN211 described in claim 1 and the composition described in claim 2 in the preparation of a product for reducing uric acid.

5. The application according to claim 4, wherein Use of the Lactiplantibacillus plantarum CN211 described in claim 1 and the composition described in claim 2 in the preparation of a product for alleviating the symptoms of hyperuricemia.

6. Use of the Lactiplantibacillus plantarum CN211 described in claim 1 and the composition described in claim 2 in the preparation of a product for protecting against kidney injury.

7. Use of the Lactiplantibacillus plantarum CN211 described in claim 1 and the composition described in claim 2 in the preparation of a product for enhancing the antioxidant capacity of the liver.

8. Use of Lactiplantibacillus plantarum CN211 according to claim 1 and the composition according to claim 2 in the preparation of an antibacterial agent, characterized in that, The antibacterial activity is against Streptococcus anginosus, Vibrio parahaemolyticus, and / or Helicobacter pylori.

9. A composition, characterized in that, The composition contains the Lactiplantibacillus plantarum CN211 described in claim 1 and Bifidobacterium longum subsp. longum CN973. The Bifidobacterium longum subsp. longum CN973 is deposited in the China Center for Type Culture Collection. The deposition date is May 28, 2024, and the deposition number is CCTCC NO: M 20241083.

10. Use of the composition described in claim 9 in the preparation of a product for enhancing body immunity.

11. Use of the composition described in claim 9 in the preparation of a product for enhancing the antioxidant capacity of the liver.

Images